Navigation Links
China Sky One Medical, Inc. Develops Nasal Spray for Rheumatic Disease
Date:8/14/2008

HARBIN, China, Aug. 14 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. (''China Sky One Medical'' or ''the Company'') (Amex: CSY), a leading fully integrated pharmaceutical company producing external use, over-the-counter drugs in the People's Republic of China ("PRC"), today announced that it successfully developed a nasal spray for the treatment and prevention of rheumatic disease.

Heilongjiang Tianlong Pharmaceutical, Inc. (''Tianlong''), a wholly-owned subsidiary of China Sky One Medical, Inc., recently completed research and development for the spray, which includes the active ingredients Naphazoline Hydrochloride Chlorpheniramine Maleate and Benzalkonium Bromide. Rheumatic diseases are shown in common sympathies and characterized by joint inflammation. There are currently only five other manufacturers of the spray in China and China Sky One has obtained the necessary approvals for production.

''We are very excited about the development of this spray, which serves a huge market in China,'' said Mr. Yan-Qing Liu, Chairman, CEO and President of China Sky One Medical, Inc. ''We expect to launch the spray in the fourth quarter of 2008, and estimate that sales will add $500,000 to revenue in the fourth quarter.''

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company (''TDR'') and Harbin First Bio- Engineering Company Limited ("First"), the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

For more information, please contact:

Company Contact:

China Sky One Medical, Inc.

Mr. Yu-Bo Hao, Board Secretary

Tel: +86-451-5399-4069

Email: china_sky_one@yahoo.cn

Investor Relations Contact:

CCG Investor Relations

Mr. Crocker Coulson, President

Tel: +1-646-213-1915

Email: crocker.coulson@ccgir.com

Mr. Richard Micchelli

Financial Writer

Tel: +1-646-454-4516

Email: richard.micchelli@ccgir.com

Web: http://www.ccgir.com


'/>"/>
SOURCE China Sky One Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Bio Energy Holdings Group Reports Second Quarter 2008 Financial Results
2. China Biologic Products Establishes Governance and Nominating Committee and Compensation Committee
3. China Medicine Announces Strong Second Quarter 2008 Results
4. China Biologic Products Announces Second Quarter 2008 Results Conference Call
5. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
6. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
7. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
8. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
9. China Nepstar Chain Drugstore to Announce Second Quarter 2008 Financial Results on August 27
10. China Pharma Holdings, Inc. Announces Second Quarter 2008 Financial Results
11. China Biologic Products Begins Annual Maintenance of its Production Facilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... CA (PRWEB) , ... August 15, 2017 , ... ... pioneering graphene biosensors that accelerate pharmaceutical and biotherapeutics development, announces the launch of ... number of steps needed to gain kinetic binding data for a wide range ...
(Date:8/15/2017)... , ... August 15, 2017 , ... The Conference ... on Immuno-Oncology 360° (IO360°) programming through a series of upcoming panels and events. The ... 7-9, 2018, at The Roosevelt Hotel in New York City. , “With our experience ...
(Date:8/14/2017)... , ... August 14, 2017 , ... ... essential device-to-computer interconnect using USB or PCI Express, announced the release of SYZYGY™, ... is intended to satisfy the need for a compact, low cost, low pin-count, ...
(Date:8/11/2017)... ... ... Algenist continues to disrupt the skincare industry with today’s debut of GENIUS Liquid ... the key structural element skin needs to maintain its youthful appearance and Algenist is ... First to market with proprietary collagen water active , Active ...
Breaking Biology Technology:
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... The research team of The Hong Kong ... identification by adopting ground breaking 3D fingerprint minutiae recovery and matching ... and accuracy for use in identification, crime investigation, immigration control, security ... ... A research team led by ...
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
Breaking Biology News(10 mins):